Survodutide: Glucagon+GLP-1 receptor dual agonist (expected late 2020s) Another dual-action treatment, Survodutide activates glucagon receptors as well as GLP-1 receptors
For more information, see the plozasiran Deep Dive in the October 2025 edition of Primes Quarterly Drug Pipeline
What to expect: Optimization strategies: During this period, patients at Klarity Health often report their first significant non-scale victorieslike noticing clothes fitting differently or having more energy for daily activities
Brian Spears, Chief Medical Officer Dr
I wish that I had tracked my food intake, because I was really tired on 1.5 mg and I definitely wasn't eating enough food.
Mecanismo de accin distintivo: Tirzepatide es nico como agonista dual GIP/GLP-1, mientras que semaglutide, dulaglutide y liraglutide son agonistas GLP-1 puros